BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Aug 3, 2018
Clinical News

CHMP positive on patisiran, Symkevi, Humira and Neulasta biosimilars

...Xerava eravacycline from Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) to treat complicated intra-abdominal infections (cIAIs) and Ilumetri tildrakizumab...
...Endocrine/metabolic, Cancer Sandi Wong eravacycline (TP-434, IV TP-434) G-Lasta, Neulasta, Peglasta, pegfilgrastim (KRN125, SD/01) Humira, adalimumab (D2E7) Ilumya (tildrakizumab-asmn, MK-3222, sch 900222) Imfinzi...
BioCentury | Jul 27, 2018
Company News

CHMP positive on patisiran, Symkevi, Humira and Neulasta biosimilars

...Xerava eravacycline from Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) to treat complicated intra-abdominal infections (cIAIs) and Ilumetri tildrakizumab...
...on NSE. Sandi Wong eravacycline (TP-434, IV TP-434) G-Lasta, Neulasta, Peglasta, pegfilgrastim (KRN125, SD/01) Humira, adalimumab (D2E7) Ilumya (tildrakizumab-asmn, MK-3222, sch 900222) Imfinzi...
BioCentury | Jun 30, 2018
Product Development

Defining access potential - before it’s too late

...treat moderate-to-severe asthma has a PDUFA date of Oct. 20. In March, FDA approved Ilumya tildrakizumab-asmn...
BioCentury | Apr 6, 2018
Finance

Fundamentally driven

...pain associated with postherpetic neuralgia Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA) FDA approves Ilumya tildrakizumab-asmn (MK-3222...
BioCentury | Mar 23, 2018
Clinical News

Sun's IL-23 psoriasis mab approved by FDA

...Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA) said FDA approved Ilumya tildrakizumab-asmn (MK-3222) to treat adults with...
...Inc. (NYSE:MRK), Kenilworth, N.J. Product: Ilumya tildrakizumab (MK-3222) Business: Autoimmune Allison Johnson Ilumya (tildrakizumab-asmn, MK-3222, sch 900222) tildrakizumab (MK-3222, sch 900222) Tremfya...
BioCentury | Mar 21, 2018
Company News

Sun's IL-23 mAb gets FDA approval for psoriasis

...Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA) said FDA approved Ilumya tildrakizumab-asmn (MK-3222) to treat adults with...
...Stock Exchange on Wednesday. The company announced the news after Indian market hours. Allison Johnson tildrakizumab (MK-3222, sch 900222) Tremfya...
BioCentury | Feb 28, 2018
Distillery Therapeutics

Cancer

...of CLL. Merck & Co. Inc., Almirall S.A. and Sun Pharmaceutical Industries Ltd. have tildrakizumab (MK-3222...
BioCentury | Jul 13, 2017
Company News

Almirall lowers guidance

...BioCentury, July 10 ). Almirall said it expects to launch another psoriasis candidate, tildrakizumab ( MK-3222...
...is an oral dimethyl fumarate targeting nuclear factor (erythroid-derived 2)-like 2 ( NFE2L2 ; NRF2). Tildrakizumab...
...subunit alpha ( IL23P19 ; IL-23A). Almirall S.A. (Madrid:ALM), Barcelona, Spain Business: Dermatology, Autoimmune Jaime De Leon Acticlate doxycycline LAS41008 MK-3222 Skilarence tildrakizumab Merck...
BioCentury | Jul 10, 2017
Financial News

Almirall sags after lowering guidance

...BioCentury Extra, June 27) . Almirall said it expects to launch another psoriasis candidate, tildrakizumab (MK-3222...
...NRF2). Tildrakizumab is a humanized mAb against IL-23 subunit alpha ( IL23P19 ; IL-23A). Jaime De Leon Acticlate doxycycline LAS41008 MK-3222 Skilarence tildrakizumab Almirall...
Items per page:
1 - 10 of 29